Stock Scorecard



Stock Summary for Kamada Ltd (KMDA) - $5.95 as of 11/19/2024 4:48:14 AM EST

Total Score

20 out of 30

Currently on the following lists
Growth Stock List
Tim's Recommendation
Buy

Growth List Algorithm Criteria for KMDA

Positive earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for KMDA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for KMDA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for KMDA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for KMDA (30 out of 90)

Stock Price Rating (Max of 10) 4
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 0
Book Value (Max of 10) 3
Book Value to Price (Max of 10) 1
Analyst Buy Ratings (Max of 5) 2
Analyst Strong Buy Ratings (Max of 5) 3
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 3
Trading Volume (Max of 10) 3
Price to Earnings (Max of 10) 7

Latest News for for KMDA

Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 11/7/2024 1:00:00 PM
Alvotech Attending Citi's Global Healthcare Conference on December 4, 2024, and Evercore's HealthCONx Conference on December 5, 2024 11/7/2024 1:00:00 PM
Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024 - Kamada ( NASDAQ:KMDA ) 11/6/2024 12:00:00 PM
Alvotech to Report Financial Results for the First Nine Months of 2024 on November 13, 2024, and Host Conference Call on November 14, 2024, at 8:00 am ET - Alvotech ( NASDAQ:ALVO ) 10/30/2024 12:30:00 PM
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 10/25/2024 12:00:00 PM
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 10/25/2024 12:00:00 PM
Alvotech Meeting Investors and Presenting at the Jefferies 2024 London Healthcare Conference on November 19-20, 2024 - Alvotech ( NASDAQ:ALVO ) 10/25/2024 12:00:00 PM
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® ( ustekinumab ) 10/22/2024 11:00:00 AM
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® ( ustekinumab ) 10/22/2024 11:00:00 AM
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ ( ustekinumab-aekn ) , Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® ( ustekinumab ) 10/22/2024 11:00:00 AM

Financial Details for KMDA

Company Overview

Ticker KMDA
Company Name Kamada Ltd
Country USA
Description Kamada Ltd. develops, produces and markets plasma-derived protein therapies for orphan indications. The company is headquartered in Rehovot, Israel.
Sector Name LIFE SCIENCES
Industry Name PHARMACEUTICAL PREPARATIONS
Most Recent Quarter 6/30/2024
Next Earnings Date N/A

Stock Price History

Last Day Price 5.95
Price 4 Years Ago 6.48
Last Day Price Updated 11/19/2024 4:48:14 AM EST
Last Day Volume 93,992
Average Daily Volume 44,133
52-Week High 6.53
52-Week Low 4.60
Last Price to 52 Week Low 29.35%

Valuation Measures

Trailing PE 21.52
Industry PE 22.60
Sector PE 40.32
5-Year Average PE -25.22
Free Cash Flow Ratio 6.07
Industry Free Cash Flow Ratio 12.03
Sector Free Cash Flow Ratio 27.97
Current Ratio Most Recent Quarter 4.08
Total Cash Per Share 0.98
Book Value Per Share Most Recent Quarter 4.24
Price to Book Ratio 1.33
Industry Price to Book Ratio 5.31
Sector Price to Book Ratio 20.88
Price to Sales Ratio Twelve Trailing Months 2.21
Industry Price to Sales Ratio Twelve Trailing Months 11.82
Sector Price to Sales Ratio Twelve Trailing Months 7.11
Analyst Buy Ratings 1
Analyst Strong Buy Ratings 1

Share Statistics

Total Shares Outstanding 57,492,000
Market Capitalization 342,077,400
Institutional Ownership N/A

Dividends

Ex-Dividend Date N/A
Last Dividend Amount 0.00
Current Dividend Amount 0.00
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 100.00%
Annual Earnings Growth 456.92%
Reported EPS 12 Trailing Months 0.27
Reported EPS Past Year 0.19
Reported EPS Prior Year 0.15
Net Income Twelve Trailing Months 12,379,000
Net Income Past Year 8,284,000
Net Income Prior Year -2,321,000
Quarterly Revenue Growth YOY 13.40%
5-Year Revenue Growth 4.81%
Operating Margin Twelve Trailing Months 0.13

Balance Sheet

Total Cash Most Recent Quarter 56,547,000
Total Cash Past Year 55,641,000
Total Cash Prior Year 34,258,000
Net Cash Position Most Recent Quarter 56,547,000
Net Cash Position Past Year 42,678,000
Long Term Debt Past Year 12,963,000
Long Term Debt Prior Year 12,963,000
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 0.95
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 242,001,450
Total Stockholder Equity Prior Year 176,020,000
Total Stockholder Equity Most Recent Quarter 250,358,056

Free Cash Flow

Free Cash Flow Twelve Trailing Months 6,580,125
Free Cash Flow Per Share Twelve Trailing Months 0.11
Free Cash Flow Past Year -1,559,123
Free Cash Flow Prior Year 24,802,000

Options

Put/Call Ratio 0.00
Has Options False
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.15
MACD Signal 0.16
20-Day Bollinger Lower Band 5.04
20-Day Bollinger Middle Band 5.61
20-Day Bollinger Upper Band 6.18
Beta 0.20
RSI 52.67
50-Day SMA 5.15
150-Day SMA 0.00
200-Day SMA 5.36

System

Modified 11/19/2024 4:48:15 AM EST